Therapy News and Research

RSS

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, presented nonclinical data on PV-10 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD.

29 Oct 2012

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Sea water therapy is a technique of cellular nutrition backed by more than 100 years of clinical use in hospitals, during which numerous studies have demonstrated its beneficial effects on patients' health.

29 Oct 2012

Cellectis announces successful programming of immune system cells to kill cancer cells

Cellectis, the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris.

29 Oct 2012

Tumor count in the breast an important consideration for providing radiation therapy

Not all women diagnosed with operable breast cancer present with a single tumor; some have multifocal disease appear in the breast, which means multiple tumors found in the same breast quadrant, while others have multicentric disease, where multiple tumors are found in separate breast quadrants. Multifocal or multicentric disease is not a standard indication to receive radiation after mastectomy. For patients who undergo lumpectomy, radiation dose and extent is not altered based on multifocal or multicentric disease compared to patients presenting with a single tumor.

29 Oct 2012

Alternate method to precisely tag breast cancer tumors

When surgeons operate to remove a tumor, determining exactly where to cut can be tricky. Ideally, the entire tumor should be removed while leaving a continuous layer of healthy tissue, but current techniques for locating the tumors during surgery are imprecise. Now a multidisciplinary team from the University of California, San Diego, is developing an alternate means of precisely tagging breast cancer tumors for removal or targeted destruction.

29 Oct 2012

First Edition: October 29, 2012

Today's headlines include reports about how the presidential election's outcome could impact the insurance industry as well as the fate of people who are sick or uninsured.

29 Oct 2012

New therapy to treat rare form of cystic fibrosis works in unconventional way, scientists say

Scientists at the Hospital for Sick Children in Toronto have established that a drug recently approved by the U.S. Food and Drug Administration to treat a rare form of cystic fibrosis works in an unconventional way.

29 Oct 2012

UK remains at risk of devastating stroke crisis, new report confirms

The UK remains at risk of a devastating stroke crisis, according to UK health experts launching Reports published today, on World Stroke Day, by Action for Stroke Prevention, an alliance of renowned health experts and patient organisations.

29 Oct 2012

FDA clears MAQUET’s new SENSATION PLUS 7.5Fr. 40cc intra-aortic balloon catheter

MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE mark approval for its new SENSATION PLUS 7.5Fr. 40cc intra-aortic balloon (IAB) catheter.

29 Oct 2012

Drug-eluting stents exhibit some benefits in patients over 80

Rarely tested in patients over the age of 80, a study found that drug-eluting stents exhibited some benefits over bare-metal stents, though both types of stents demonstrated a clinical benefit. Results of the XIMA trial were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

29 Oct 2012

New research report shows how bimatoprost causes human hair to regrow

If you're balding and want your hair to grow back, then here is some good news. A new research report appearing online in The FASEB Journal shows how the FDA-approved glaucoma drug, bimatoprost, causes human hair to regrow.

29 Oct 2012

New findings on early treatment of ADHD patients presented at AACAP 2012 conference

Mayo Clinic researchers are presenting new findings on the early treatment of child and adolescent attention deficit hyperactivity disorder this week at the American Academy of Childhood and Adolescent Psychiatry annual meeting in San Francisco.

29 Oct 2012

St. Luke's cardiologist wins TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award

Barry D. Rutherford, MD, a world renowned interventional cardiologist, was presented the TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award in a ceremony held today during the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

29 Oct 2012

Post-radiation drop in testosterone linked to recurrence of prostate cancer in men

Men whose testosterone drops following radiation therapy for prostate cancer are more likely to experience a change in PSA levels that signals their cancer has returned, according to new research from Fox Chase Cancer Center.

29 Oct 2012

Resistin protein causes high levels of bad cholesterol

Canadian scientists have discovered that a protein called resistin, secreted by fat tissue, causes high levels of "bad" cholesterol (low-density lipoprotein or LDL), increasing the risk of heart disease.

29 Oct 2012

ESDM improves social skills and brain responses to social cues

The Early Start Denver Model, a comprehensive behavioral early intervention program that is appropriate for children with autism spectrum disorder as young as 12 months, has been found to be effective in improving social skills and brain responses to social cues in a randomized controlled study published online today in the Journal of the American Academy of Child & Adolescent Psychiatry.

29 Oct 2012

Study identifies genetic variations as predictors of prostate cancer-related fatigue

Researchers at Moffitt Cancer Center and the University of South Florida have found that men with prostate cancer who receive androgen deprivation therapy may predictably suffer from fatigue if they have single nucleotide polymorphisms in three pro-inflammatory genes. The discovery highlights the importance of personalized medicine, in which therapies are tailored to a patient's genetic profile.

29 Oct 2012

Therapy News and Research

Nonclinical data on Provectus PV-10 oncology drug presented at 27th SITC

Sea water strengthens the body against viruses, low defences, bacteria and pathogens

Cellectis announces successful programming of immune system cells to kill cancer cells

Tumor count in the breast an important consideration for providing radiation therapy

Alternate method to precisely tag breast cancer tumors

First Edition: October 29, 2012

New therapy to treat rare form of cystic fibrosis works in unconventional way, scientists say

UK remains at risk of devastating stroke crisis, new report confirms

FDA clears MAQUET’s new SENSATION PLUS 7.5Fr. 40cc intra-aortic balloon catheter

Drug-eluting stents exhibit some benefits in patients over 80

New research report shows how bimatoprost causes human hair to regrow

New findings on early treatment of ADHD patients presented at AACAP 2012 conference

St. Luke's cardiologist wins TCT 2012 Geoffrey O. Hartzler Master Clinical Operator Award

Post-radiation drop in testosterone linked to recurrence of prostate cancer in men

Resistin protein causes high levels of bad cholesterol

ESDM improves social skills and brain responses to social cues

Study identifies genetic variations as predictors of prostate cancer-related fatigue

Flu shot might also prevent heart disease

Europe remains at risk of a devastating stroke crisis

Pfizer receives FDA approval for Synribo to treat chronic myelogenous leukemia

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News